SAT-554 Teprotumumab in Graves' Orbitopathy: Extended Outcome Analyses

Objective A multicenter, double-masked, randomized, placebo-controlled, phase two trial of 88 patients with active, moderate-to-severe Graves’ orbitopathy (GO) has demonstrated a significant and rapid response to teprotumumab, an insulin-like growth factor 1 receptor inhibitory monoclonal antibody,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kahaly, George, Douglas, Raymond, Holt, Robert, Francis-Sedlak, Megan, Perdok, Renee, Sile, Saba, Smith, Terry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Thyroid
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552477/
http://dx.doi.org/10.1210/js.2019-SAT-554

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552477/
http://dx.doi.org/10.1210/js.2019-SAT-554

Ejemplares similares